Nova Scotia Health Authority

Quick facts

Marketed products

• Aggressive Blood Pressure control
• Chloroprocaine Injection · Anesthesia
  Chloroprocaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.
• Controlled Release Morphine · Pain Management
  Morphine binds to opioid receptors in the central and peripheral nervous system to reduce pain perception and provide analgesia.
• Fleet Enema
• Mepivacaine Injection · Anesthesia
  Mepivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of nerve impulses.
• Prostagladin · Other
• TCA · Psychiatry, Pain Management
  TCA inhibits the reuptake of norepinephrine and serotonin in the central nervous system, increasing their synaptic availability.

Phase 3 pipeline

• acetaminophen plus codeine · Pain management
  Acetaminophen acts as a non-selective COX inhibitor, while codeine exerts its effects through opioid receptors.
• acetaminophen plus ibuprofen · Pain management
  Acetaminophen works by inhibiting the production of prostaglandins, which are chemicals that cause pain and fever, while ibuprofen works by inhibiting the enzyme COX-2, which is involved in the production of prostaglandins.

Phase 1 pipeline

• Combination Tylenol and Ibuprofen

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Nova Scotia Health Authority portfolio CI brief
• Nova Scotia Health Authority pipeline updates RSS

Frequently asked questions about Nova Scotia Health Authority

Related

• Aggressive Blood Pressure control
• Chloroprocaine Injection · Anesthesia
• Controlled Release Morphine · Pain Management
• Fleet Enema
• Mepivacaine Injection · Anesthesia
• Sector hub: All tracked pharma companies